INTRODUCTION: Several studies have highlighted the role of interleukin-6 (IL-6) 
as an early signal of the inflammatory response following acute ischemic stroke. 
This study examines the potential advantage of employing high-sensitivity 
(hs)-IL-6 as a possible biomarker at the early stages of acute stroke for 
identifying an acute phase response and its potential rheological and clinical 
implications.
METHODS: Venous blood was obtained from 186 stroke patients within 24 h of 
hospital admission and 3-5 days thereafter in order to characterize an 
inflammatory and hemorheological profile (including erythrocyte aggregation). 
Neurological state was assessed by the National Institutes of Health Stroke 
Scale (NIHSS) and the modified Rankin scale (mRs).
RESULTS: While most biomarkers displayed elevated concentrations with time, 
serum concentrations of hs-IL-6 declined 3-5 days following acute stroke. 
Initially elevated levels of hs-IL-6 at presentation further correlated with 
unfavorable clinical outcomes (by NIHSS and mRs) at both time points. Analysis 
of variance in the different quartiles identified an hs-IL-6 gradient-dependent 
correlation at both time points, such that the higher the initial hs-IL-6 
concentration, the higher the elevation in inflammatory biomarkers and the 
poorer the neurological state at both time points (p<0.001 for NIHSS and p=0.001 
for mRs, for trend across quartiles).
CONCLUSIONS: This study demonstrates the potential of employing hs-IL-6 as an 
early stage biomarker for the prognosis of acute ischemic stroke. Such an 
advance would provide the means to identify at an early stage the patients who 
would require closer clinical surveillance and/or administration of therapeutic 
interventions.